Paragon 28 Inc (FNA)
7.87
+0.20
(+2.61%)
USD |
NYSE |
May 24, 16:00
7.87
0.00 (0.00%)
After-Hours: 17:06
Paragon 28 Research and Development Expense (Quarterly): 7.584M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 7.584M |
| December 31, 2023 | 8.102M |
| September 30, 2023 | 7.244M |
| June 30, 2023 | 7.683M |
| March 31, 2023 | 7.049M |
| December 31, 2022 | 6.55M |
| September 30, 2022 | 6.337M |
| June 30, 2022 | 5.99M |
| Date | Value |
|---|---|
| March 31, 2022 | 5.773M |
| December 31, 2021 | 4.874M |
| September 30, 2021 | 4.118M |
| June 30, 2021 | 3.587M |
| March 31, 2021 | 3.549M |
| December 31, 2020 | 2.997M |
| September 30, 2020 | 2.346M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.346M
Minimum
Sep 2020
8.102M
Maximum
Dec 2023
5.586M
Average
5.99M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Stryker Corp | 368.00M |
| Alphatec Holdings Inc | 18.01M |
| Globus Medical Inc | 57.27M |
| Orthofix Medical Inc | 19.49M |
| iRhythm Technologies Inc | 16.99M |